Article
The Drug Olaparib Reduces Recurrence Among Those With Early-Stage, High-Risk Breast Cancer
People with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence may benefit from treatment with Lynparza (olaparib).
People with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence may benefit from treatment with Lynparza (olaparib) for the year after completing chemotherapy, surgery or radiation according to the recently completed OlympiA study. While Herceptin (trastuzumab) can reduce recurrence in those with HER2-positive breast cancer, no targeted therapy was available to keep cancer from returning in people with HER2-negative, BRCA-positive breast cancer until the development of olaparib, a PARP inhibitor. The American Society of Clinical Oncology (ASCO) updated their guidelines to recommend olaparib in the year following breast cancer treatment in these patients. Read more in our XRAY review.
